Mycophenolate

Among fully vaccinated individuals with rheumatic diseases, breakthrough COVID-19 infections occurred most commonly in patients treated with B cell depleting agents or mycophenolate, according to data presented at ACR Convergence 2021.

Patients with chronic inflammatory disease on immunosuppressants, especially B-cell depleting agents, mycophenolate and glucocorticoids, exhibited poor antibody responses to the mRNA vaccine for COVID-19, according to a presenter here.

Having well controlled disease is the first and most important step to a safe pregnancy in patients with lupus, according to a presenter at the 2021 Congress of Clinical Rheumatology-West.

Rheumatologists opt for therapy regimens that include rituximab more often than nephrologists in treating refractory lupus nephritis or renal flare in children, according to data published in Pediatric Rheumatology.

Adding mycophenolate mofetil to a glucocorticoid in first-line treatment for immune thrombocytopenia improves response and decreases the risk for refractory or relapsed disease, according to data.

Voclosporin, when added to mycophenolate mofetil and low-dose steroids, results in higher complete renal response rates in patients with lupus nephritis, compared with mycophenolate mofetil and low-dose steroids alone, according to data.

Concomitant use of mycophenolate mofetil with pegloticase demonstrated clinically meaningful improvement in 86% of patients with uncontrolled gout, compared with pegloticase alone, according to data published in Arthritis & Rheumatology.

The addition of mycophenolate to standard first-line steroid treatment appeared effective for patients with newly diagnosed immune thrombocytopenia, according to study results presented at the virtual ASH Annual Meeting and Exposition.